A Prospective Study of Lipoprotein(a) and Risk of Coronary Heart Disease Among Women with Type 2 Diabetes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2005 Jun 23

PMID 15971061

Citations 14

Authors

I Shai

M B Schulze

J E Manson

M J Stampfer

N Rifai

F B Hu

Affiliations

Soon will be listed here.

Abstract

Aims: We examined the association between lipoprotein (Lp)(a) and CHD among women with type 2 diabetes.

Methods: Of 32,826 women from the Nurses' Health Study who provided blood at baseline, we followed 921 who had a confirmed diagnosis of type 2 diabetes.

Results: During 10 years of follow-up (6,835 person-years), we documented 122 incident cases of CHD. After adjustment for age, smoking, BMI, glycosylated HbA(1)c, triglycerides (TGs), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and other cardiovascular risk factors, the relative risk (RR) comparing extreme quintiles of Lp(a) was 1.95 (95% CI 1.07-3.56). The association was not appreciably altered after further adjustment for apolipoprotein B(100) or several inflammatory biomarkers. Increasing levels of Lp(a) were associated with lower levels of TGs. The probability of developing CHD over 10 years was higher among diabetic women with substantially higher levels of both Lp(a) (>1.07 micromol/l) and TGs (>2.26 mmol/l) than among diabetic women with lower levels (22 vs 10%, p log-rank test=0.049). Diabetic women with a higher level of only Lp(a) or TGs had a similar (14%) risk. In a multivariate model, diabetic women with higher levels of Lp(a) and TGs had an RR of 2.46 (95% CI 1.21-5.01) for developing CHD, as compared with those with lower levels of both biomarkers (p for interaction=0.413). The RRs for women with a higher level of either Lp(a) (RR=1.22, 95% CI 0.77-1.92) or TGs (RR=1.39, 95% CI 0.78-2.42) were comparable.

Conclusions/interpretation: Increased levels of Lp(a) were independently associated with risk of CHD among diabetic women.

Citing Articles

Serum/plasma biomarkers and the progression of cardiometabolic multimorbidity: a systematic review and meta-analysis.

Jin Y, Xu Z, Zhang Y, Zhang Y, Wang D, Cheng Y Front Public Health. 2023; 11:1280185.

PMID: 38074721 PMC: 10701686. DOI: 10.3389/fpubh.2023.1280185.

Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience.

Dal Pino B, Gorini F, Gaggini M, Landi P, Pingitore A, Vassalle C J Clin Med. 2023; 12(3).

PMID: 36769413 PMC: 9918149. DOI: 10.3390/jcm12030764.

Correlations Between Coronary Artery Disease, Coronary Artery Calcium Score, and Lipoprotein(a) Level in Korea.

Kim J, Choi S, Lee Y, Lee J, Chung H, Woo J Ther Clin Risk Manag. 2022; 18:981-987.

PMID: 36212048 PMC: 9533785. DOI: 10.2147/TCRM.S374372.

Metabolic syndrome, lipoprotein(a) and subclinical atherosclerosis in Mexican population.

Cardoso-Saldana G, Gonzalez-Salazar M, Posadas-Sanchez R, Vargas-Alarcon G Arch Cardiol Mex. 2020; 91(3):307-314.

PMID: 33268905 PMC: 8351643. DOI: 10.24875/ACM.20000276.

Levels of Apolipoprotein A1, B100 and Lipoprotein (a) in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People.

Patel V, Patel K, Makadia M, Shah A, Chaudhari K, Nilayangode H J Clin Diagn Res. 2017; 11(2):BC01-BC05.

PMID: 28384849 PMC: 5376851. DOI: 10.7860/JCDR/2017/22741.9258.

References

Carlson L, Hamsten A, Asplund A . Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989; 226(4):271-6. DOI: 10.1111/j.1365-2796.1989.tb01393.x. View

Hernandez C, Chacon P, Simo R . Differential influence of LDL cholesterol and triglycerides on lipoprotein(a) concentrations in diabetic patients. Diabetes Care. 2001; 24(2):350-5. DOI: 10.2337/diacare.24.2.350. View

Reblin T, Rader D, Beisiegel U, Greten H, BREWER Jr H . Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. Atherosclerosis. 1992; 94(2-3):223-32. DOI: 10.1016/0021-9150(92)90247-e. View

Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y . Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care. 1995; 18(2):241-4. DOI: 10.2337/diacare.18.2.241. View

Marcovina S, Albers J, Scanu A, Kennedy H, Giaculli F, Berg K . Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000; 46(12):1956-67. View

Gonbert S, Malinsky S, Sposito A, Laouenan H, Doucet C, Chapman M . Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis. 2002; 164(2):305-11. DOI: 10.1016/s0021-9150(02)00072-2. View

Scanu A, Edelstein C . Kringle-dependent structural and functional polymorphism of apolipoprotein (a). Biochim Biophys Acta. 1995; 1256(1):1-12. DOI: 10.1016/0005-2760(95)00012-2. View

Hu F, Meigs J, Li T, Rifai N, Manson J . Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53(3):693-700. DOI: 10.2337/diabetes.53.3.693. View

Rath M, Niendorf A, Reblin T, Dietel M, Krebber H, Beisiegel U . Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989; 9(5):579-92. DOI: 10.1161/01.atv.9.5.579. View

10.

. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979; 28(12):1039-57. DOI: 10.2337/diab.28.12.1039. View

11.

Haffner S . Dyslipidemia management in adults with diabetes. Diabetes Care. 2003; 27 Suppl 1:S68-71. DOI: 10.2337/diacare.27.2007.s68. View

12.

Craig W, Ledue T . Lipoprotein(a) and the acute phase response. Clin Chim Acta. 1992; 210(3):231-2. DOI: 10.1016/0009-8981(92)90209-9. View

13.

Gaubatz J, Heideman C, Gotto Jr A, Morrisett J, Dahlen G . Human plasma lipoprotein [a]. Structural properties. J Biol Chem. 1983; 258(7):4582-9. View

14.

Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G . Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 1996; 16(12):1568-72. DOI: 10.1161/01.atv.16.12.1568. View

15.

Manson J, Rimm E, Stampfer M, Colditz G, Willett W, Krolewski A . Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet. 1991; 338(8770):774-8. DOI: 10.1016/0140-6736(91)90664-b. View

16.

Werba J, Safa O, Gianfranceschi G, Michelagnoli S, Sirtori C, Franceschini G . Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis. 1993; 101(2):203-11. DOI: 10.1016/0021-9150(93)90117-d. View

17.

Berglund L, Carlstrom K, Stege R, Gottlieb C, Eriksson M, Angelin B . Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab. 1996; 81(7):2633-7. DOI: 10.1210/jcem.81.7.8675589. View

18.

Gazzaruso C, Garzaniti A, Falcone C, Puija A, Geroldi D, Giordanetti S . Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients. J Diabetes Complications. 2003; 17(3):135-40. DOI: 10.1016/s1056-8727(02)00192-7. View

19.

Pai J, Curhan G, Cannuscio C, Rifai N, Ridker P, Rimm E . Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem. 2002; 48(10):1781-4. View

20.

Rand M, Sangrar W, Hancock M, Taylor D, Marcovina S, Packham M . Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998; 18(9):1393-9. DOI: 10.1161/01.atv.18.9.1393. View